&nbsp;

NursingPracticeContinuum.pdf

Jun 2021

Drug

niraparib

Other Name(s): Zejula

Quick Link(s):

Drug Monograph, Patient Info Sheet

Mar 2025

Regimen

NIVL+IPIL

Cancer Type:

Lung,

Mesothelioma (Pleural)

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jul 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded),

ipilimumab (Unfunded)

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jul 2025

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

MFOLFOX6+NIVL

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

NPAC(W)+PEMB

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

New Drug Funding Program

Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

May 2024

Regimen

NIVL

Cancer Type:

Gastrointestinal,

Esophagus

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Aug 2024

Measuring Ontario’s Small Area Inequalities in Cancer (MOSAIC) Study

Document

MOSAIC_Placemat.pdf

Jan 2022

Document

mosaicPlacemat.jpg

Feb 2022

Document